Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

86-8010 for domestic callers and 617-801-6888 for international callers. When prompted, the passcode is 11977886.

For a copy of Par's Form 10-Q for the second quarter ended June 28, 2008, visit Investors/SEC Filings on the Par web site at http://www.parpharm.com.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENS
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Greg Schlicht and Dax Denman Join as Company ... Algenol Biofuels, developers of,DIRECT TO ETHANOL(TM), the ... continued growth of the company with the,appointments Greg ... General Counsel and Dax Denman as Senior Program ...
... Insmed Inc. (Nasdaq:,INSM) a developer of follow-on biologics ... of Insmed, will present at the,Biosimilars 2008 Conference ... Company,s perspective on the potential impact of follow-on ... a panel on this topic on,Tuesday, September 23, ...
... Study of More Than 60,000 Women Underscores Need for Better ... Implications and Risks Associated with Osteoporosis, MONTREAL, Sept. 15 ... (GLOW) showed that 55 percent of women,diagnosed with osteoporosis do ... their peers. This latest study from GLOW included more than,60,000 ...
Cached Biology Technology:Algenol Biofuels Further Strengthens Team With Key Appointments 2Insmed to Present at Biosimilars 2008 Conference 2Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 2Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 3
(Date:4/17/2014)... the University of Texas Medical Branch at Galveston ... treated with radiation for cervical cancer should begin ... , The UTMB researchers, finding a high incidence ... treated with radiation, offer new recommendations that the ... screening about eight years after their initial cervical ...
(Date:4/17/2014)... led by the Australian National University (ANU), have ... and deep-sea temperature variability over the past 5.3 ... understand the climate surrounding ice ages over the ... the relationship between carbon dioxide levels, global temperatures ... University of Southampton (UoS) and the National Oceanography ...
(Date:4/16/2014)... 20-year assessment of Nicaragua,s legal, artisanal green sea turtle ... catch rates of turtles in what may have become ... Wildlife Conservation Society and University of Florida. , During ... 170,000 green turtles were killed between 1991 and 2011, ...
Breaking Biology News(10 mins):Radiation therapy for cervical cancer increases risk for colorectal cancer 2Ancient sea-levels give new clues on ice ages 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... cancer cells that survive chemotherapy leaving the door ... Institute scientists developed an original method for imaging and ... how a chemotherapy drug affects each one. ... and Eran Eden in the lab of Prof. Uri ...
... Munich, Germany and Ann Arbor, MI, USA, Jan 28 ... has joined the Illumina-Connect program, linking them to the ... new tools and applications for Illumina-generated data. , ... Munich, Germany commented: "As the industry,s only provider of ...
... observe in another but have never actually experienced yourself? A ... answer this question. The research, published by Cell Press in ... provides insight into brain mechanisms involved in empathy. Brain-imaging ... feel their own emotions or observe the same emotions in ...
Cached Biology News:Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug 2Genomatix joins Illumina-Connect program 2I feel your pain: Neural mechanisms of empathy 2
... Lauryl Ether 30% concentration ... Preservative. Surfactant. Clear Solution. ... is 1 mL of ... added to 400 mL ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
... Contact Printing Kit contains choice of Printing Surface (3 ... over Ti adhesion layer, 1 silicon wafer coated with ... 3 plain glass slides) and PDMS Stamps (3 PDMS ... squares or 100 um x 10 mm or 200 ...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: